202 related articles for article (PubMed ID: 33844165)
1. Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective study.
Lanzolla G; Menconi F; Nicolì F; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Dec; 44(12):2575-2579. PubMed ID: 33844165
[TBL] [Abstract][Full Text] [Related]
2. Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.
Leo M; Sabini E; Ionni I; Sframeli A; Mazzi B; Menconi F; Molinaro E; Bianchi F; Brozzi F; Santini P; Elisei R; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2018 Mar; 41(3):357-361. PubMed ID: 28856610
[TBL] [Abstract][Full Text] [Related]
3. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids.
Menconi F; Marinò M; Pinchera A; Rocchi R; Mazzi B; Nardi M; Bartalena L; Marcocci C
J Clin Endocrinol Metab; 2007 May; 92(5):1653-8. PubMed ID: 17299076
[TBL] [Abstract][Full Text] [Related]
4. Total thyroid ablation in Graves' orbitopathy.
Menconi F; Leo M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2015 Aug; 38(8):809-15. PubMed ID: 25740065
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves' orbitopathy (GO): a prospective, randomized, single-blind clinical trial.
Moleti M; Violi MA; Montanini D; Trombetta C; Di Bella B; Sturniolo G; Presti S; Alibrandi A; Campennì A; Baldari S; Trimarchi F; Vermiglio F
J Clin Endocrinol Metab; 2014 May; 99(5):1783-9. PubMed ID: 24432992
[TBL] [Abstract][Full Text] [Related]
6. Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial.
Leo M; Marcocci C; Pinchera A; Nardi M; Megna L; Rocchi R; Latrofa F; Altea MA; Mazzi B; Sisti E; Profilo MA; Marinò M
J Clin Endocrinol Metab; 2012 Jan; 97(1):E44-8. PubMed ID: 22031515
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
[TBL] [Abstract][Full Text] [Related]
8. Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.
Li HX; Xiang N; Hu WK; Jiao XL
J Endocrinol Invest; 2016 Nov; 39(11):1225-1233. PubMed ID: 27220843
[TBL] [Abstract][Full Text] [Related]
9. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.
De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A
Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963
[TBL] [Abstract][Full Text] [Related]
10. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
[TBL] [Abstract][Full Text] [Related]
11. VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY.
Leo M; Mautone T; Ionni I; Profilo MA; Sabini E; Menconi F; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
Endocr Pract; 2016 Oct; 22(10):1177-1186. PubMed ID: 27732097
[TBL] [Abstract][Full Text] [Related]
12. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis.
Vannucchi G; Campi I; Covelli D; Dazzi D; Currò N; Simonetta S; Ratiglia R; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2009 Sep; 94(9):3381-6. PubMed ID: 19567525
[TBL] [Abstract][Full Text] [Related]
13. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
Lanzolla G; Ricci D; Nicolì F; Sabini E; Sframeli A; Brancatella A; Mantuano M; Dottore GR; Bucci I; Figus M; Nardi M; Latrofa F; Marcocci C; Marinò M
J Endocrinol Invest; 2020 Dec; 43(12):1759-1768. PubMed ID: 32583374
[TBL] [Abstract][Full Text] [Related]
14. [Graves' ophthalmopathy].
Eckstein A; Esser J
Internist (Berl); 2010 May; 51(5):584, 586-8, 590-2, passim. PubMed ID: 20383481
[TBL] [Abstract][Full Text] [Related]
15. Natural history of graves' orbitopathy after treatment.
Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
[TBL] [Abstract][Full Text] [Related]
16. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
[TBL] [Abstract][Full Text] [Related]
17. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy.
Moleti M; Mattina F; Salamone I; Violi MA; Nucera C; Baldari S; Lo Schiavo MG; Regalbuto C; Trimarchi F; Vermiglio F
Thyroid; 2003 Jul; 13(7):653-8. PubMed ID: 12964971
[TBL] [Abstract][Full Text] [Related]
18. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
[No Abstract] [Full Text] [Related]
19. Current concepts regarding Graves' orbitopathy.
Bartalena L; Tanda ML
J Intern Med; 2022 Nov; 292(5):692-716. PubMed ID: 35604323
[TBL] [Abstract][Full Text] [Related]
20. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
Woo YJ; Jang SY; Lim TH; Yoon JS
Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]